Otsuka Pharmaceutical Companies (U.S.)’s Post

More than 13 million people in the U.S. are affected by post-traumatic stress disorder (PTSD). PTSD may affect mental, physical, social, and/or the spiritual well-being of a person. Today, we are pleased to announce, in collaboration with Lundbeck, the submission of a supplemental New Drug Application (sNDA) for U.S. FDA review of brexpiprazole as a combination therapy with sertraline for the treatment of PTSD in adults. We will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health. Learn more here: https://lnkd.in/e7WQbNsF #DefyLimitation

More than 13 million people in the U.S. are affected by post-traumatic stress disorder (PTSD). PTSD may affect mental, physical, social, and/or the spiritual well-being of a person. Today, we are pleased to announce, in collaboration with Lundbeck, the submission of a supplemental New Drug Application (sNDA) for U.S. FDA review of brexpiprazole as a combination therapy with sertraline for the treatment of PTSD in adults. We will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health. Learn more here: https://lnkd.in/edcucBJY #DefyLimitation

More than 13 million people in the U.S. are affected by post-traumatic stress disorder (PTSD). PTSD may affect mental, physical, social, and/or the spiritual well-being of a person. Today, we are pleased to announce, in collaboration with Lundbeck, the submission of a supplemental New Drug Application (sNDA) for U.S. FDA review of brexpiprazole as a combination therapy with sertraline for the treatment of PTSD in adults. We will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health. Learn more here: https://lnkd.in/eD3d-S2x #DefyLimitation

More than 13 million people in the U.S. are affected by post-traumatic stress disorder (PTSD). PTSD may affect mental, physical, social, and/or the spiritual well-being of a person. Today, we are pleased to announce, in collaboration with Lundbeck, the submission of a supplemental New Drug Application (sNDA) for U.S. FDA review of brexpiprazole as a combination therapy with sertraline for the treatment of PTSD in adults. We will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health. Learn more here: https://lnkd.in/eUAPJ6qJ #DefyLimitation

Recent research shows ketamine might be used to treat posttraumatic stress disorder (PTSD), at least in the short term. Ketamine moderately reduced participants' scores on several scales used to assess PTSD and depression (CAPS, PCL, MADRS), with benefits noticed as early as day 1 (Sicignano et al., 2023). However, the reduction was similar to currently recommended pharmacological treatments and the longevity of the effect still needs to be determined (Sicignano et al., 2023). More research is needed, but results so far suggest ketamine might be useful short term or when traditional medications aren’t an option. #mentalhealth #mentalhealthmatters #mentalhealthawareness #ptsd #trauma #depression  (Sicignano et al., 2023) https://lnkd.in/etw6KNmt 

A new study shows a single dose of LSD can significantly reduce anxiety in 48% of patients and provide lasting results! A dose of MM120 (lysergide d-tartrate) led to a 48% rate of remission from generalized anxiety disorder at 12 weeks following the drug’s administration, according to MindMed. The MM120 drug also significantly improved clinical signs of generalized anxiety disorder for 65% of patients within three months. Anxiety is the most common mental disorder in the United States, affecting over 40 million people age 18 and older each year, according to the Anxiety and Depression Association of America. This therapy has secured breakthrough designation by the FDA which means it will get accelerated evaluation and could be available sooner for prescription use! These are exactly the types of breakthroughs and agency cooperation needed to address the mental health crisis. 🤞 #psychedelics #mentalhealth #anxietyrelief #breakthroughtreatment Article Link: https://lnkd.in/gw3tkAU5

As studies accumulate it will be interesting to see for who and which populations benefit from classic psychedelic types..

Did you know? Gov. Wes Moore has declared this week Tardive Dyskinesia Awareness Week. Many people living with serious mental illnesses (for example, bipolar disorder, major depressive disorder, schizophrenia, and schizoaffective disorder) or gastrointestinal disorders may be treated with medications that work as dopamine receptor blocking agents, including antipsychotics and antiemetics. While ongoing treatment with these medications can be necessary, prolonged use is associated with tardive dyskinesia (TD), an involuntary movement disorder that is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, and fingers or toes that can impact people physically, socially, and emotionally. This #TDAwarenessWeek, we’re encouraging healthcare providers to initiate patient conversations to identify the possibility of drug-induced movement disorders, like tardive dyskinesia (TD). Access a questionnaire to help facilitate a dialogue: bit.ly/4ban08r #Screen4TD

🌟 Exciting Possibilities in Mental Health Treatment! 🌈 Could a groundbreaking new generation of drugs, inspired by psychedelics, potentially revolutionize the treatment of depression, PTSD, and other disorders? Recent clinical trials have been showing incredibly promising outcomes, sparking hope for transformative therapies. 🧪 If you're conducting research in this area, look no further! TRC offers an extensive range of research chemicals, including various psychedelic compounds, to support your important work. 🔬 Explore our diverse selection of products here: https://okt.to/h0piTS #MentalHealthResearch #PsychedelicMedicine #TransformativeTherapies #ResearchChemicals #Innovation

Mental disorders significantly impact global public health due to their prevalence, disabling nature, and negative effect on quality of life. Despite advancements in understanding these disorders, many patients do not benefit from first-line treatments, highlighting the need for alternative therapies. Over the last fifty years, the discovery of the endocannabinoid system has sparked interest in using cannabinoids—both natural and synthetic—as potential treatments for mental disorders including major depression, bipolar disorder, anxiety, PTSD, and schizophrenia. This summary underlines that while there are promising therapeutic benefits of cannabinoids for these conditions, the associated risks also necessitate further detailed research to validate their efficacy and safety. 🌱Disclaimer: This Video/Post is for educational and informational purposes only For More Information/News Follow Us: Get Your MMJ Card Click The Link In Our Bio: . . . #wearesunjane #mentaldisorder #publichealth #MentalHealthMonth #mentalhealthawarness #PTSD #florida #usa #medicalcannabis